Janssen Pharmaceutical K.K.
Quick facts
Phase 3 pipeline
- CNTO 148 · Immunology
CNTO 148 is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling in immune-mediated diseases. - ITCZ-IV · Infectious Disease
ITCZ-IV is an intravenous formulation of itraconazole, a triazole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. - ITCZ Oral Solution · Infectious Disease
ITCZ (itraconazole) is an azole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. - JNS001 · Immunology
JNS001 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to modulate immune response. - JNS020QD · Diabetes
JNS020QD is a small molecule that targets the SGLT2 receptor. - Placebo A (After CP)
Placebo A is an inert control substance with no active pharmacological mechanism. - Placebo B (After CP)
Placebo B is an inert control substance with no active pharmacological mechanism.
Phase 2 pipeline
- CNTO 1959 · Immunology
CNTO 1959 is a monoclonal antibody that inhibits IL-23 signaling to reduce inflammatory immune responses. - ExPEC4V
- JNJ-54861911, 50 mg
- JNJ-63733657
- PegIFNα-2a
- Tramadol Hydrochloride; JNS013
Phase 1 pipeline
- Erdafitinib Intravesical Delivery System
- JNJ 10229570-AAA 1.2%
- JNJ 10229570-AAA 2.4% cream
- JNJ 10229570-AAA 3.6%
- JNJ-212082
- JNJ-56021927 120 Milligram
- JNJ-56021927 240 Milligram
- JNJ-56021927 60 Milligram
- JNS002
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: